Clinical trial
Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive…
NCT00387400 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00387400 |
|---|---|
| Title | Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme |
| Official title | A Phase I Study of Temozolomide and RAD001C in Patients With Malignant Glioblastoma Multiforme |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug, Genetic, Other |
| Interventions | everolimus, temozolomide, microarray analysis, immunohistochemistry staining method |
| Enrollment | 32 |
| Start date | Mar 20, 2007 |
| Primary completion | Sep 24, 2010 |
| Completion | Jan 6, 2012 |
| First posted | Oct 13, 2006 |
| Last update posted | Aug 4, 2023 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: